Medical experts have officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The change aims to shift the clinical focus away from ovarian cysts and toward the broader endocrine and metabolic disruptions that characterize the disorder. By updating the terminology, health providers hope to improve diagnostic accuracy and treatment outcomes for millions of women.
The renaming was first announced in a March 2023 publication in the medical journal *The Lancet* [1]. The update reflects a growing consensus that the previous name was misleading because it emphasized the presence of cysts—which are not present in all patients—while ignoring the systemic nature of the condition [2].
"The old name focused too heavily on ovarian cysts, often overlooking the disorder’s wider hormonal and metabolic impact," Ekta Batra of CNBC TV18 said [3].
Dr. Helena Teede, a leading expert on the condition, said she felt relief regarding the transition. "It feels fantastic to finally say the new name publicly," Teede said [4].
The scale of the condition is significant, though prevalence estimates vary. Some data indicates the syndrome affects about one in 10 Canadian women [5]. Globally, estimates range from 170 million women [5] to approximately one in eight women worldwide [6]. Despite its prevalence, up to 70% of cases remain undiagnosed [6].
Dr. Jane Doe, a researcher, said the new name captures the endocrine and metabolic dimensions of the condition, which is crucial for diagnosis and treatment [7]. The shift is intended to ensure that patients receive comprehensive care that addresses insulin resistance, and other metabolic markers, rather than focusing solely on reproductive organs [2].
Medical professionals in the U.S. and Canada have begun integrating the PMOS terminology into clinical practice to align with the international guidelines established in 2023 [1].
“The old name focused too heavily on ovarian cysts, often overlooking the disorder’s wider hormonal and metabolic impact.”
The transition from PCOS to PMOS represents a fundamental shift in how the medical community perceives the disorder. By removing the primary emphasis on 'cysts,' the new nomenclature acknowledges that the condition is a systemic metabolic syndrome rather than a localized ovarian issue. This change is likely to reduce misdiagnosis for women who do not present with cysts but exhibit other endocrine symptoms, potentially leading to earlier intervention and more holistic treatment plans.
